Big Apple in crisis over soaring egg prices
'It's crazy. They're just soooo expensive', says a Lulu Lemon mum returning from a morning jog on Park Avenue. 'I need my post-workout eggs.'
At Salt's Cure, a Tik-Tok famous brunch spot in Greenwich village, the proprietor has strategically placed cards next to the till to see off any potential egg-rage.
'Due to rising costs, the price of eggs has increased by 25 cents per egg,' the neatly printed cards explain. 'We appreciate your understanding and continued support.'
Meanwhile, at a Whole Foods uptown, the egg crisis enveloping the Big Apple has left the shelves eerily barren.
And at delis across the city, shopkeepers have taken to selling 'loosies' – single eggs for those unable to fork out $13 for a dozen.
The unprecedented surge in US egg prices is being driven by the H5N1 bird flu epidemic which has ravaged America's cattle and poultry farms.
More than 166 million commercial birds have had to be culled over the last three years, causing egg prices to soar and many consumers to become outraged.
'WTF, it's cheaper to paint an avocado than buy an egg this Easter!', notes a widely shared social media post this week.
Eggs are a staple of the American diet in a way that they are not quite in Britain.
Whether you live in a pile dwelling in Louisiana or in a high-rise on the Upper East Side they dominate menus and home cooking.
Pancakes, waffles, tortillas, huevos rancheros and donuts are everywhere.
And just as the Inuits have 412 words for snow, Americans have a highly developed egg-related lexicon.
You can't go to a diner without knowing the difference between 'over medium' and 'over easy', for example.
The shortage has become so acute that eggs are now being smuggled in their millions from Mexico, where they cost just $2 per dozen on average (an $11 saving).
Since October, US Customs and Border Protection (CBP) have made 3,768 poultry-related seizures at the border – almost 10 times the number of fentanyl interceptions during the same period.
The Trump administration is now scrambling to try and ease the hit on consumers and replenish stock by importing eggs from abroad.
Trump himself said at a press conference recently that 'the only problem with eggs was Joe Biden,' adding that prices are now 'way down,' – a statement that has been widely disputed.
Deals have already been secured with Turkey and South Korea, and others like Poland and Lithuania have reportedly been approached by the US government for talks about exporting their eggs too.
'When our chicken populations are repopulated and we've got a full egg laying industry going again, hopefully in a couple of months, we then shift back to our internal egg layers and move those eggs out onto the shelf,' Agriculture Secretary Brooke Rollins told reporters at the White House last week.
Back in Manhattan, New Yorkers are finding creative ways to cope.
Over 50 delis across the city have introduced the 'Bird Flu Bailout' sandwich as an alternative to the classic bacon, egg, and cheese that's been the city's go-to hangover cure since the 1960s.
The sandwich was created by the San Francisco startup 'Just Egg' and uses a mung bean-based substitute for eggs to craft the iconic take-away.
'Plants don't get the flu. Try one of our plant-based egg breakfast items today,' the sandwich's promotional ad reads.
Protect yourself and your family by learning more about Global Health Security
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hill
20 minutes ago
- The Hill
Proposed rule bans nearly all abortions at VA hospitals
The VA said in the proposal that it is reversing a 2022 rule that for the first time allowed the department to provide abortions in limited circumstances to pregnant veterans and their eligible family members, even in states that banned abortion after the Supreme Court overturned Roe v. Wade. Between 1999 and 2022, the VA excluded almost all abortions and abortion counseling for veterans and their families from their medical benefits package. By reversing the rule, officials are seeking to ensure taxpayer dollars are not used to terminate pregnancies, according to a filing released Friday. They also called the Biden administration's decision to implement the interim rule 'inappropriate' and 'legally questionable.' A final rule could come as soon as the public comment period on the measure closes on Sept. 3. Reproductive rights groups said the move robbed service members of the ability to control their bodies and their futures. 'Since taking office, the Trump administration has repeatedly attacked service members, veterans, and their families' access to basic reproductive care, including gender-affirming care,' Alexis McGill Johnson, president and CEO of Planned Parenthood Federation of America, said, referring to the VA's decision in March to stop providing transgender veterans with hormone therapy. 'Taking away access to health care shows us that the Trump administration will always put politics and retribution over people's lives.' Anti-abortion groups, meanwhile, applauded the Trump administration's decision, calling it a 'major win' for the movement. 'Instead of prioritizing the real and urgent needs of our veterans, the Biden-Harris Administration turned VA hospitals into abortion centers – violating longstanding law and betraying the will of the American people who strongly oppose forced taxpayer-funded abortions,' the anti-abortion group Susan B. Anthony Pro-Life America said in a statement. 'Thankfully, this injustice is now corrected.'
Yahoo
37 minutes ago
- Yahoo
Why Curaleaf Stock Popped by 15% on Monday
Key Points Good news benefiting the cannabis industry was beneficial for the company too. There were pot-positive developments on both the medical and political fronts. 10 stocks we like better than Curaleaf › Pardon the use of the adjective, but it was obvious on Monday that the market has high hopes for cannabis company Curaleaf (OTC: CURLF). Investors piled into the stock after some positive news developments affecting its industry hit the headlines. By the time the smoke had cleared, Curaleaf was left standing with a more than 15% gain in its stock price that day. This obliterated the 1.4% advance of the S&P 500 index. Drug of choice The first news item producing that buzz was research published by the influential American Medical Association (AMA). In its Journal of the American Medical Association, the AMA detailed research from a survey that evaluated a clutch of drugs for how they affected eating disorders. Of the numerous drugs tested, the Journal noted, cannabis and psychedelic compounds were the highest-rated for alleviating symptoms of eating disorders. On top of that, marijuana and the psychedelics LSD and psilocybin also performed well in terms of overall mental health. These contrasted with the generally weak showing of nicotine and alcohol, which the Journal said were frequently ranked by the respondents as being the most harmful substances. Marijuana is legally sold as a medicine to qualifying patients in most U.S. states. If the drug can indeed treat eating disorders, this could dramatically enhance its appeal as a medical drug. Pot lobbying Another item of interest was Federal Election Commission (FEC) filings cited by several media outlets revealing that a pot industry-supported political action committee (PAC) made a meaty donation to President Trump's MAGA Inc. This is a so-called "super PAC" entitled to raise unlimited amounts of money to support political figures. The American Rights and Reform PAC, fueled by donations from marijuana companies, has donated $1 million to MAGA Inc. Although that's relatively small given the over $177 million the latter absorbed in the first six months of the year, this does indicate that the weed industry is actively lobbying influential people in U.S. politics. Should you buy stock in Curaleaf right now? Before you buy stock in Curaleaf, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Curaleaf wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Curaleaf Stock Popped by 15% on Monday was originally published by The Motley Fool Sign in to access your portfolio

Miami Herald
2 hours ago
- Miami Herald
enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company
- enVVeno is developing the VenoValve as a potential treatment option for the approximately 2.5 million patients in the U.S. suffering from severe deep Chronic Venous Insufficiency - FDA decision expected in 2H'2025 - Access the "What This Means" segment here IRVINE, CA / ACCESS Newswire / August 4, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it participated in a Virtual Investor "What This Means" segment entitled, "enVVeno Medical - Making Veins Work Again - How President Trump's CVI Diagnosis is Raising Awareness." Rob Berman, CEO and Dr. Marc Glickman, CMO of enVVeno Medical discussed the progressive nature of chronic veinous insufficiency and whether President Trump may one day be a candidate for the VenoValve® following U.S. Food and Drug Administration (FDA) approval. The Company estimates that there are approximately 2.5 million patients in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the FDA, with a decision anticipated in the second half of 2025. The "What This Means" segment can be accessed here. About CVI Severe deep venous CVI is a serious and debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments that repair deep venous valve dysfunction, the #1 cause of severe CVI-a disease estimated to cost the U.S. healthcare system in excess of $26 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. INVESTOR CONTACT: Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation